Reeve will serve as chair of the audit committee.
Reeve is a distinguished industry veteran who brings over 20 years of global financial experience across pharmaceutical, medical device and bio-pharma companies.
She currently serves as chief financial officer at Constellation Pharmaceuticals and oversaw the company's transition to a public company in July 2018.
Prior to joining Constellation, she served as interim chief financial officer and corporate controller of Parexel International, a global biopharmaceutical services company, where she was responsible for all aspects of finance, investor relations, procurement and facilities and oversaw the financial aspects of a USD 5bn leveraged buy-out to take the company private.
Reeve previously served as chief financial officer of both Inotek and Aton Pharma, and held senior finance and operational positions at Bristol-Myers Squibb (NYSE: BMY), Merck (NYSE: MRK) and Novartis. She currently serves on the board of PTC Therapeutics.
Ribon Therapeutics is a clinical stage biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.
Its lead program is RBN-2397, a first-in-class PARP7 inhibitor in clinical development for the treatment of cancer. Ribon is located in Cambridge, Massachusetts.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project